DURHAM, N.C. — Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action...
Latest News
DURHAM, N.C. — Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily. DM is a rare systemic autoimmune disease characterized by progressive muscle weakness and extensive,...
DURHAM, N.C. — Priovant today announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States. LPP inflammation targets the stem cell-rich bulge region of the hair follicle (the permanent portion responsible for hair growth),...
CAMBRIDGE, Mass. — Prize4life and the Alzheimer Research Forum announce the release of the ALS Forum (www.ResearchALS.org), a web-based resource for researchers interested in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease. The site is modeled on the Alzheimer Research Forum’s popular website, www.alzforum.org,...
Berlin, Germany – ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the successful completion of a sprint project to deliver clinical material. The partnership focused on an integrated and accelerated chemistry, manufacturing,...
Researchers have made progress in developing malaria vaccines over the past few decades, but the goal remains a daunting challenge. Malaria has evolved to thwart almost every aspect of the human immune system. On March 16-17, 2009, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National...
VERO BEACH, Fla. — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at...
OKLAHOMA CITY – Progentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced today an 18-month collaborative research agreement with GlaxoSmithKline (GSK) to evaluate novel measurement and management tools for systemic lupus erythematosus (“SLE” or “lupus”). At least 5 million people worldwide are living with...
CAMBRIDGE, Mass. –Progentos Therapeutics, a biotechnology company developing regenerative medicines for multiple sclerosis (MS) and other demyelinating diseases, today announced that the first participant has been dosed in its Phase 1/2a clinical trial of PRO-1562 (NCT07826689). PRO-1562 is a novel oral small molecule designed to regenerate myelin in patients with...
BUFFALO, NY- February 28, 2024 – A new research paper was published in Aging Volume 16, Issue 3, entitled, “Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.” Mounting studies indicate that oxidative stress (OS) significantly contributes to tumor progression. In this new study,...
